June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
BCVA changes after suprachoroideal graft of autologous cells in Dry AMD
Author Affiliations & Notes
  • Paolo G. Limoli
    Low Vision Research Center, Milan, Italy
  • Enzo M Vingolo
    Departement of Ophthalmology, Polo Pontino - La Sapienza University, Rome, Italy
  • Marcella Nebbioso
    Department of Sense Organs and Ocular Electrofisiology Center, La Sapienza University, Rome, Italy
  • Sergio Zaccaria Scalinci
    Department of Ophthalmology, Bologna University, Bologna, Italy
  • Luigi Mele
    Departement of Ophthalmology, II University of Naples, Naples, Italy
  • Celeste Limoli
    Low Vision Research Center, Milan, Italy
  • Footnotes
    Commercial Relationships Paolo Limoli, None; Enzo Vingolo, None; Marcella Nebbioso, None; Sergio Zaccaria Scalinci, None; Luigi Mele, None; Celeste Limoli, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2259. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paolo G. Limoli, Enzo M Vingolo, Marcella Nebbioso, Sergio Zaccaria Scalinci, Luigi Mele, Celeste Limoli; BCVA changes after suprachoroideal graft of autologous cells in Dry AMD. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2259. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Our prior study (ARVO 2014, Medicine© 2014, in press) showed in eyes affected by Dry AMD a significant improvement of ERG data, recorded after the suprachoroidal autologous graft. We used three different types of autologous cells: adipocytes, present in the orbital fat dislocated in the suprachoroidal space, platelets, derivated from Platelet Rich Plasma (PRP) and adipose derived stem-cells (ADSCs), included in tissue adipose’s stromal vascular fractions (SVF), both grafted by suprachoroidal lipofilling. The study analyzes whether, in eyes affected by Dry AMD, the suprachoroidal graft of these cells can improve the BCVA over time.


We studied two groups of patients, both affected by Dry AMD, with BCVA equal to or greater than 1 logMAR.<br /> Group A consisted of 11 eyes of 8 patients (age average: 71.5 years), treated with autologous suprachoroidal graft by Limoli Retinal Restoration Tecnique (LRRT). Group B consisted of 14 eyes of 12 patients (age average: 80.4), used as a control variable. For each patient diagnosis has been verified by SD-OCT (Zeiss Cirrus) and microperimetry (Maia or MP1). Before the graft (T0), BCVA (Logmar) and close up visus (pts), maximal, scotopic and photopic ERG (μV), according to standard ISCEV, have been considered. BCVA was measured also at T90 and at T180.


In Group A, following LRRT, BCVA changed from 0.581 (T0) to 0.504 (T90) to 0.376 logM (T180) (+32.20%). In the control Group, BCVA changed from 0.573 (T0) to 0.587 (T90) to 0.601 logM (T180) (-4.75%). No negatives side effects occured in either case.


In patients with dry AMD who received LRRT treatment, BCVA can increase in six months, compared to the control group. All implanted cells can produce a lot of growth factors (bFGF, VEGF, PEDF, IL, M-CSF, GM-CSF, PlGF PDGF, ecc.), with neurotrophic and angiotrophic properties, ensuring a constant secretion of growth factors in a choroidal flow. From the choroidal layer, growth factors could reach retinal photoreceptors. Interaction with membrane receptors of retinal cells can activate an intracellular pathway. Consequently, we can have in the cell nucleus genic responses. We can obtain an antiapoptotic effect which can explain the neuroenhancement. This suggests a greater potential increase of BCVA in the grafted group.  

BCVA changes after 6 months from suprachoroidal autologous graft.
BCVA changes after 6 months from suprachoroidal autologous graft.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.